Algorithm-based flow cytometric diagnosis (486 validation cases)
| . | WHO diagnosis . | n . | Algorithm-based flow cytometric diagnosis . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL . | CD10− DLBCL . | CD10+ DLBCL . | CLL . | FL . | HCL . | LPL . | MCL . | MZL . | NC . | Sensitivity . | Specificity . | PPV . | NPV . | |||
| T1 to T5 | BL | 13 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 54.1 ± 13.8% | 98.9 ± 0.5% | 59.3 ± 12.4% | 98.7 ± 0.4% |
| CD10− DLBCL | 31 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 21 | 16.2 ± 6.6% | 99.3 ± 0.4% | 63.4 ± 18.1% | 94.6 ± 0.4% | |
| CD10+ DLBCL | 33 | 4 | 0 | 7 | 0 | 1 | 0 | 0 | 0 | 0 | 21 | 21.0 ± 6.9% | 98.2 ± 0.6% | 46.8 ± 12.8% | 94.5 ± 0.5% | |
| CLL | 125 | 0 | 0 | 0 | 112 | 0 | 0 | 0 | 0 | 0 | 13 | 89.7 ± 2.7% | 99.7 ± 0.3% | 99.1 ± 0.9% | 96.6 ± 0.9% | |
| FL | 109 | 1 | 0 | 8 | 0 | 34 | 0 | 1 | 0 | 0 | 65 | 31.3 ± 4.5% | 99.7 ± 0.2% | 97.2 ± 2.6% | 83.4 ± 0.9% | |
| HCL | 38 | 0 | 0 | 0 | 0 | 0 | 34 | 0 | 0 | 0 | 4 | 89.4 ± 5.2% | 99.8 ± 0.2% | 97.2 ± 2.6% | 99.1 ± 0.4% | |
| LPL | 54 | 0 | 2 | 0 | 0 | 0 | 0 | 17 | 1 | 2 | 32 | 31.4 ± 6.1% | 99.5 ± 0.3% | 89.2 ± 6.9% | 92.1 ± 0.6% | |
| MCL | 56 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 41 | 0 | 14 | 73.2 ± 5.8% | 99.5 ± 0.3% | 95.4 ± 3.1% | 96.6 ± 0.7% | |
| MZL | 27 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 7 | 16 | 26.4 ± 8.4% | 98.5 ± 0.5% | 50.7 ± 12.2% | 95.8 ± 0.5% | |
| T1 + T2 | BL | 13 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 53.8 ± 13.5% | 97.7 ± 0.7% | 39.4 ± 9.5% | 98.7 ± 0.4% |
| CD10− DLBCL | 31 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 28 | 6.7 ± 4.5% | 99.6 ± 0.3% | 50.9 ± 28.6% | 94.0 ± 0.3% | |
| CD10+ DLBCL | 33 | 7 | 0 | 8 | 0 | 1 | 1 | 0 | 0 | 0 | 16 | 24.7 ± 7.4% | 97.6 ± 0.7% | 42.8 ± 10.1% | 94.7 ± 0.5% | |
| CLL | 125 | 0 | 0 | 0 | 108 | 0 | 0 | 0 | 0 | 1 | 16 | 86.3 ± 3.0% | 99.7 ± 0.3% | 99.1 ± 0.9% | 95.5 ± 0.9% | |
| FL | 109 | 4 | 1 | 10 | 0 | 37 | 0 | 0 | 0 | 1 | 56 | 33.8 ± 4.4% | 99.5 ± 0.4% | 95.1 ± 3.3% | 83.9 ± 0.9% | |
| HCL | 38 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 1 | 26 | 28.8 ± 7.4% | 99.8 ± 0.2% | 91.4 ± 8.3% | 94.3 ± 0.6% | |
| LPL | 54 | 0 | 1 | 0 | 0 | 1 | 0 | 8 | 1 | 1 | 42 | 15.0 ± 4.8% | 99.5 ± 0.3% | 80.4 ± 12.9% | 90.4 ± 0.5% | |
| MCL | 56 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 26 | 0 | 28 | 46.3 ± 6.8% | 99.5 ± 0.3% | 92.8 ± 4.8% | 93.4 ± 0.8% | |
| MZL | 27 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 23 | 3.6 ± 3.5% | 98.9 ± 0.5% | 17.3 ± 17.9% | 94.6 ± 0.2% | |
| . | WHO diagnosis . | n . | Algorithm-based flow cytometric diagnosis . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL . | CD10− DLBCL . | CD10+ DLBCL . | CLL . | FL . | HCL . | LPL . | MCL . | MZL . | NC . | Sensitivity . | Specificity . | PPV . | NPV . | |||
| T1 to T5 | BL | 13 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 54.1 ± 13.8% | 98.9 ± 0.5% | 59.3 ± 12.4% | 98.7 ± 0.4% |
| CD10− DLBCL | 31 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 21 | 16.2 ± 6.6% | 99.3 ± 0.4% | 63.4 ± 18.1% | 94.6 ± 0.4% | |
| CD10+ DLBCL | 33 | 4 | 0 | 7 | 0 | 1 | 0 | 0 | 0 | 0 | 21 | 21.0 ± 6.9% | 98.2 ± 0.6% | 46.8 ± 12.8% | 94.5 ± 0.5% | |
| CLL | 125 | 0 | 0 | 0 | 112 | 0 | 0 | 0 | 0 | 0 | 13 | 89.7 ± 2.7% | 99.7 ± 0.3% | 99.1 ± 0.9% | 96.6 ± 0.9% | |
| FL | 109 | 1 | 0 | 8 | 0 | 34 | 0 | 1 | 0 | 0 | 65 | 31.3 ± 4.5% | 99.7 ± 0.2% | 97.2 ± 2.6% | 83.4 ± 0.9% | |
| HCL | 38 | 0 | 0 | 0 | 0 | 0 | 34 | 0 | 0 | 0 | 4 | 89.4 ± 5.2% | 99.8 ± 0.2% | 97.2 ± 2.6% | 99.1 ± 0.4% | |
| LPL | 54 | 0 | 2 | 0 | 0 | 0 | 0 | 17 | 1 | 2 | 32 | 31.4 ± 6.1% | 99.5 ± 0.3% | 89.2 ± 6.9% | 92.1 ± 0.6% | |
| MCL | 56 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 41 | 0 | 14 | 73.2 ± 5.8% | 99.5 ± 0.3% | 95.4 ± 3.1% | 96.6 ± 0.7% | |
| MZL | 27 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 7 | 16 | 26.4 ± 8.4% | 98.5 ± 0.5% | 50.7 ± 12.2% | 95.8 ± 0.5% | |
| T1 + T2 | BL | 13 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 53.8 ± 13.5% | 97.7 ± 0.7% | 39.4 ± 9.5% | 98.7 ± 0.4% |
| CD10− DLBCL | 31 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 28 | 6.7 ± 4.5% | 99.6 ± 0.3% | 50.9 ± 28.6% | 94.0 ± 0.3% | |
| CD10+ DLBCL | 33 | 7 | 0 | 8 | 0 | 1 | 1 | 0 | 0 | 0 | 16 | 24.7 ± 7.4% | 97.6 ± 0.7% | 42.8 ± 10.1% | 94.7 ± 0.5% | |
| CLL | 125 | 0 | 0 | 0 | 108 | 0 | 0 | 0 | 0 | 1 | 16 | 86.3 ± 3.0% | 99.7 ± 0.3% | 99.1 ± 0.9% | 95.5 ± 0.9% | |
| FL | 109 | 4 | 1 | 10 | 0 | 37 | 0 | 0 | 0 | 1 | 56 | 33.8 ± 4.4% | 99.5 ± 0.4% | 95.1 ± 3.3% | 83.9 ± 0.9% | |
| HCL | 38 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 1 | 26 | 28.8 ± 7.4% | 99.8 ± 0.2% | 91.4 ± 8.3% | 94.3 ± 0.6% | |
| LPL | 54 | 0 | 1 | 0 | 0 | 1 | 0 | 8 | 1 | 1 | 42 | 15.0 ± 4.8% | 99.5 ± 0.3% | 80.4 ± 12.9% | 90.4 ± 0.5% | |
| MCL | 56 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 26 | 0 | 28 | 46.3 ± 6.8% | 99.5 ± 0.3% | 92.8 ± 4.8% | 93.4 ± 0.8% | |
| MZL | 27 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 23 | 3.6 ± 3.5% | 98.9 ± 0.5% | 17.3 ± 17.9% | 94.6 ± 0.2% | |
The upper half of the table describes the results when tubes 1 to 5 of the B-CLPD panel are used; the bottom half tabulates the results from the same validation set cases using tubes 1 and 2 of the B-CLPD panel only. Mean plus SD of sensitivity, specificity, PPV, and NPV were calculated by bootstrapping.
NC, not classified, NPV, negative predictive value; PPV, positive predictive value.